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Renin stim dating properties of parathyroid hormone-related peptide in
the isolated perfused rat kidney. Previous studies showed that PTHrP
exhibits renal vasodilating, arteriolar cAMP stimulating and receptor
binding properties. The present experiments were designed to study
whether PTHrP may influence renin secretion. Rat kidneys were
isolated and single-pass perfused at constant flow and stabilized pres-
sure. Exposures to PTHrP or PTH stimulated a dose-dependent renin
release reaching similar Vmax. The affinity (0.1 nM) and threshold
concentration (0.01 nM) for PTHrP were about 10 times lower than for
Ff11. Compared to 10 MM isoproterenol, the maximum renin responses
to PTHrP were similar but of shorter duration. The PTHrP dose-
response curve was not affected by 10 jiM indomethacin. Administered
simultaneously, PTHrP and PTH displayed no additive effects. PTHrP-
induced renin release as well as the role of extracellular calcium were
further studied in nonfiltering kidneys, which were perfused at a
constant flow and stable pressure in a closed circuit. Basal renin release
was inversely related with perfusate calcium and was depressed by the
calcium ionophore BAY-K8644. PTHrP (100 nM) induced a 1.6-fold
increase of basal renin release in normocalcic perfusate. Removing
calcium abolished renin responses. PTHrP reversed the inhibiting
effects of hypercalcic media or BAY-K8644 on basal renin release. The
results support calcium-mediated renin stimulating properties for
PTHrP, via PTH receptors, independently from baroreceptors, macula
densa and prostaglandins.
Parathyroid hormone-related peptide (PTHrP) has been
shown to be the primary tumor-derived hypercalcemic factor
involved in the pathogenesis of tumor-associated hypercalce-
mia [reviewed in 1—4]. PTH and PTHrP are expressed by
different genes and are immunologically distinct but have lim-
ited homology in the amino-terminus portion. PTH and PTHrP
share the same target tissues and possess common physiologi-
cal properties, including stimulation of bone resorption and
elevation of blood calcium concentration.
Like PTH, PTHrP interacts with cardiovascular tissues.
When administered systematically, PTHrP reduces blood pres-
sure, increases blood flow and/or decreases vascular resistance
in the kidney, muscle and skin [5, 6]. In vitro, PTHrP vasore-
laxes isolated segments of the rabbit renal artery [7] and helical
strips of the rat aorta [5]. Furthermore, an increasing number of
normal tissues [8—101, including extravascular [10—14] and vas-
cular smooth muscles [8—10, 14, 15], express mRNA for PTHrP
or PTHrP itself. Thus, in contrast to PTH, which is exclusively
secreted by the parathyroid glands, PTHrP could serve as a
local modulator of regional microcirculation.
We recently studied whether this peptide may be active on
the intrarenal vascular bed. In rabbit renal microvessel prepa-
rations enriched in glomerular arterioles, both PTHrP and PTH
were found to bind to common and saturable receptors. The
affinity and number of PTHrP receptors in the microvessels
were similar to those of renal tubules [16]. Also, PTHrP induces
a concentration-related relaxation of the rat isolated perfused
kidney (IPK) preconstricted with the prostaglandin PGF2Q [171.
As PTHrP stimulates the adenylyl cyclase activity in the
isolated renal microvessels, the cAMP system seems to be
involved in the renal vascular action of PTHrP [17]. These
influences of PTHrP on the renal vascular bed cause questions
of whether PTHrP may also influence other functions of the
renal vascular smooth muscle cells, such as renin secretion, like
many other renal vasodilators. Moreover, factors which stimu-
late renin release appear to do so mainly by lowering cytosolic
calcium and/or increasing cellular cAMP 118, 19]. In support of
such a hypothesis, we recently showed that rat(r)PTH-(1-34)
not only stimulates adenylyl cyclase in renal cortex microves-
sels or vasodilates the rat IPK [17, 20], but also stimulates renin
release, in a calcium-dependent manner from rat IPK, isolated
glomeruli and dispersed cortical cells [21, 22].
The aims of the present study were to explore the concentra-
tion-related effect of PTHrP on renin release, to compare the
renin-stimulating potency of PTHrP to that of PTH, and to ask
whether the vasodilator products of cyclooxygenase activity may
account for the renin release in response to PTHrP and whether
PTHrP and PTH stimulate renin secretion via common action
sites. Finally, we also queried lithe stimulating effect of PTHrP on
renin release is dependent on extracellular calcium. We chose to
conduct these studies in an isolated rat kidney model, perfused at
constant flow and stable pressure to obviate the involvement of
the baroreceptors in the renin release responses.
Methods
Drugs
Received for publication February 22, 1993
and in revised form April 23, 1993
Accepted for publication May 27, 1993
© 1993 by the International Society of Nephrology
Drugs were obtained from the following sources: human
(h)PTHrP-(1-34) and rat(r) PTH-(1-34) (Bachem Feinchemi-
kalien AG, Bubendorf, Switzerland; Cambridge Research Bio-
chemicals Ltd., Northwich, UK; Neosystem Laboratories,
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Strasbourg, France); the peptides were dissolved in 1 mr'i HC1
and 1 mg/mI BSA at a concentration of 0.25 m and stored in 25
d portions at —70°C; BSA, fraction V (Euromedex, Schilt-
igheim, France), was dialyzed overnight against Krebs-Hense-
leit buffer; phenylmethylsulfonyl fluoride, 8-hydroxyquinoline,
indomethacin (1 -[p-chlorobenzoyl]-5-methoxy-2-methylindole-
3-acetic acid) and (—)-isoprotereno! hydrochloride (Sigma
Chemical Co., St. Louis, Missouri, USA); (3-['251]-iodotyrosyl-
4)angiotensin I (Amersham, Buckinghamshire, UK); angioten-
sin I (Ang I, Peninsula Labs, Belmont, California, USA); rabbit
anti-Ang I (Calbiochem, La Jolla, California, USA); sodium
pentobarbital (Clin Midy, St. Jean de Ia Ruelle, France).
Studies in the single-pass open circuit rat IPK
Kidney preparation. Male Wistar rats (170 to 220 g) were
allowed free access to standard food and water. The animals
were anesthetized by an intraperitoneal injection of sodium
pentobarbital (45 mg/kg). After isolation of the kidney and
ligation of the suprarenal aorta, perfusion through the superior
mesenteric artery was started without ischemia according to the
basic description of Schurek, Brecht and Hierholzer [23] with
some modifications. After complete separation from surround-
ing connective tissue, the kidney was taken out from animal
body and put on a thermostatically-controlled holder, and
perfused in a single-pass open circuit. The perfusate was
continuously gassed with 95% 02 and 5% CO2 and warmed at
37°C. The perfusion flows, expressed as ml/min/g of controlat-
eral kidney, were adjusted to achieve a perfusion pressure of
about 80 mm Hg during the first 30 minutes and remained
constant thereafter. At least 110 minutes were allowed for
equilibration, after which the kidneys were perfused from
secondary reservoirs with perfusates containing the desired
final concentrations of drugs (peptides or isoproterenol), or
from a main reservoir with perfusate containing no drug. In
each of the six studies to be described, perfusate collections for
renin activity determination were started at the end of the
equilibration period up to a maximum of 200 minutes. Samples
of 1 ml from each collected fraction were cooled at —20°C
before assayed for renin activity. Perfusion pressures of the
infrarenal aorta were monitored continuously with a pressure
transducer (Statham P23Db; Statham Laboratories Inc., Hato
Rey, Puerto Rico). Kidney preparations in which the perfusion
flows reached about 80 mm Hg were lower than 10 ml/min/g or
those in which the overall pressure variations were higher than
12 mm Hg during the 110 to 200 minute experimental period
were systematically rejected.
Experimental protocol. Six independent groups were studied
using the single-pass open circuit IPK. Group 1 (N = 5); time
controlled kidneys received no treatment. Perfusate was col-
lected over six minute periods between 110 and 200 minutes.
Group 2 (N = 5; PTHrP dose response) kidneys were treated
with increasing concentrations of hPTHrP-(1-34) (0.01 flM to
100 flM) every 18 minutes (at 110,128,146, 164 and 182 mm) for
two minutes. Perfusate was collected over consecutive six-
minute periods between 110 and 200 minutes. At the end of each
18 minute period, or before each PTHrP treatment, an addi-
tional 10 second perfusate collection was performed. These 10
second fractions served to check that before each PTHrP
treatment, the renin release rate returned to a value similar to
that measured during the corresponding six minute period in
time control IPK. These 10 second fractions were designated as
"basal renin release checking points." The group 3 (N = 6;
PTH dose response) group was identical to group 2 except that
hPTHrP-(1-34) was replaced by rPTH-(1-34). Group 4 (N = 4)
tested the effect of indomethacin on the PTHrP dose response.
This group is completely analogous to group 2 except that 10
LM indomethacin was present in the perfusate. In group 5 (N =
4); comparative effects of maximal concentrations of rPTH-(l-
34), hPTHrP-(1-34) and isoproterenol) kidneys were treated
with 100 ni hPTHrP, 100 nM rPTH and 10 M isoproterenol at
128, 146 and 164 minutes, respectively, during two minutes.
Six-minute perfusate collections were performed as described
for group 2. Ten second perfusate collections (basal renin
release checking points) were performed before each treatment
and at 200 minutes. Group 6 (N = 6; additivity of PTHrP- and
PTH-induced renin release) kidneys were successively treated
for two minutes with 100 flM hPTHrP, 100 nM rPTH and
simultaneously with both peptides. An injection cycle time of 18
minutes was employed starting at the 128th minute and perfu-
sate collected over six minute periods as before, but the 10
second perfusate collections (basal renin release checking
points) were not performed in this final group. PTHrP and PTH
were administered in the first and second position alternatively
to rule out an interacting effect on their renin stimulatory
responses.
Perfusion media for the open circuit IPK. The basic perfusion
solution was a Krebs-Henseleit bicarbonate buffer, pH 7.4,
containing 30 m sodium lactate and 3% gelatin as the oncotic
agent. Ionized calcium concentrations (1 mM) in the perfusate
and pH were adjusted with a Ca2-pH analyzer (Ciba Corning
Diagnostic Co., Medfield, USA).
The recirculating closed circuit JPK
After complete separation from surrounding animal body as
described above, the kidney was perfused in a closed circuit by
recovering the effluent flowing from the vena cava directly into
a recirculating reservoir. The recirculating perfusion volume
was 50 ml in each experiment, and the perfusate was gassed
continuously with 95% 02 and 5% CO2. The kidney prepara-
tions were rendered nonfiltering by the use of perfusate with
high oncotic pressure (100 mglml BSA), a low perfusion pres-
sure (70 mm Hg), and by ligation of the ureter [24]. Perfusion
flows, expressed as mllmin/g of controlateral kidney, were
adjusted to achieve a perfusion pressure of 70 mm Hg during the
first 10 to 15 minutes and remained constant for the rest of the
experiment which lasted 90 minutes. Perfusion pressures of the
infrarenal aorta were monitored as described above. Flow and
pressure criteria for exclusion of kidney preparations were
similar to those described above for the open circuit.
Experimental protocol. Four independent groups, differing
by the ionized calcium content of the perfusate or the presence
of calcium effectors, were studied using the recirculating closed
circuit IPK. Each group was divided into separate time-control
(CTL) and PTHrP-treated kidney preparations. The ionized
calcium concentration in the perfusate was adjusted to either 1
m (group A) or 2 m (group B). In a third group, BAY-K8644,
a calcium channel agonist, was added into the recirculating
reservoir after 10 to 15 minutes of perfusion (group C). The last
group was perfused with calcium-free medium containing
EGTA as a calcium-chelating agent (group D). In all of the
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PTHrP-treated kidney preparations, hPTFIrP-(1-34) was added
in the recirculating reservoir at 38 minutes. In the four groups,
the time course of the PTHrP-treated preparation was com-
pared to the corresponding time-control preparation. The time
intervals taken for the time course and the sampling points were
identical, whatever the kidney groups. Perfusate samples of 50
jzl were collected at five minute intervals, beginning at the end
of the equilibration period (35 mm) up to 90 minutes, The
samples were cooled at —20°C and diluted 25 times before
assayed for renin activity.
Perfusion media for the closed circuit. The basic composition
of the perfusion solution was, in mM: glucose, 5; urea, 6; Na
oxaloacetate, 1; Na lactate, 5; Na pyruvate, 2; Na glutamate, 5;
L-methionine, 0.5; L-alanine, 2; glycine, 2; L-serine, 2; L-pro-
line, 2; L-isoleucine, 1 and L-aspartic acid, 3 in Krebs-Hense-
leit Bicarbonate buffer containing 10% fraction V BSA. Ionized
calcium and pH were adjusted as described above for the open
circuit perfusion medium. BAY-K8644 was dissolved in ethanol
at a concentration of 5 m and then further diluted in perfusion
medium to 5 /LM, then 0.2 ml of this solution was added to the
50 ml circulating medium to achieve a final concentration of 20
nM. All experiments in which BAY-K8644 was used were
performed in the dark under monochromatic light due to the
light sensitivity of this compound. PTHrP-treated kidneys re-
ceived 25 d of 250 /LM hPTHrP-(1-34) in 1 m HCI, 0.1% BSA
to achieve a concentration of 125 n in the perfusate volume.
Determination of renin activity
Twenty microliters of the various samples of perfusate were
incubated in duplicate with an excess of partially purified
angiotensinogen from rats bilaterally nephrectomized 48 hours
before, according to the method of Itoh, Carretero and Murray
[25]: 5 mivi 8-hydroxyquinoline (converting enzyme inhibitor)
and 66.6 m phosphate buffer, pH 6.5 containing 13.5 mrvt
EDTA in a total volume of 100 d for one hour at 37°C. The
amount of substrate in each tuhe ranged from 200 to 400 ng Ang
I equivalent, and the amount of generated Ang I never exceeded
5 ng per tube. The reaction was stopped by boiling for three
minutes and the addition of 0.2 ml of 66.6 m phosphate buffer,
pH 7.5 containing I mg/mI Na azide and I mg/mi BSA. After
centrifugation for 15 minutes at 2500 x g, Ang I was measured
in 0.1 ml supernatant by RIA, according to the method of
Fyhrquist et al. [26]. The various substrate preparations had
neither measurable Ang I nor renin activity. Angiotensinase
activity was also absent from substrate preparations or samples
since the recovery of added Ang I was near 100%.
Units, calculations and statistics
The rate of renin release was expressed as ng Ang I generated
in one hour incubation per minute of perfusion and normalized
per g of kidney weight, taking the weight of the controlateral
kidney as the weight of the perfused kidney (ng Ang I/hr x
min' x g1 or Ang I units).
Open circuit JFK. In groups 2 to 6, the mean renin release
rate in the six minute fractions are presented as net increase
(mean 5EM) by subtracting the corresponding mean renin
release rates obtained from group 1 (time control). The PTH
and PTHrP dose response curves were built by calculating the
overall net renin release rates during the 18 minute periods










Group 1 075 0.01 70.6 2.6 8.6 2.4 11.3 0.4 6.3 0.3
Group 2 0.71 0.04 76.1 6.4 10.1 2.6 11.8 1.1 6.8 1.1
Group 3 0.69 0.04 76.4 3.1 9.1 1.9 11.7 0.5 6.6 0.5
Group 4 0.76 0.08 80.6 3.0 7.0 2.2 11.5 0.9 7.2 0.7
GroupS 0.75 0.01 86.0 2.8 5.8 1.8 10.6 0.2 8.1 0.3
Group 6 0.71 0.05 81.5 2.8 5.8 2.7 12.0 0.8 7.2 0.4
Abbreviations are: kidney weight: KW; mean pressure (F), overall
pressure variation (/SPmax) and mean renal vascular resistance (RVR) in
the course of the experimental period. For each parameter, there was
no significant difference between the 6 groups (P > 0.100) in the
analysis of variance for single factor experiments.
following the administrations of increasing concentrations of
peptide.
Closed circuit JFK. As the perfusate recirculates in groups A
to D, renin activity measured at any time represents cumulative
activity in Ang I units. For purposes of comparisons between
time-control and PTHrP-treated preparations inside each IPK
group, the renin release time courses are presented as the net
renin activity increase from the end of the initial equilibration
period by subtracting the renin activity present at 35 minutes
from all subsequent values. The rates of renin release were
determined over the following time periods: 0 to 35 minutes, 35
to 50 minutes, 50 to 65 minutes, 65 to 80 minutes, and 80 to 90
minutes. The rate of renin release was calculated as follows:
renin release rate = (Ang I units)t2 — (Ang I units)t1/t2 — t1 (ng
Ang I units/mm), where t1 and t2 represent the beginning and
the end of the various period intervals.
As a general rule, data points obtained under the different
experimental conditions were subjected to analysis of variance
for factorial experiments [27]. When significant differences
were found, a Duncan multiple range and multiple F-test [28]
was applied to compare point by point and to identify significant
differences between individual means. A 95% confidence level
(P cc 0.05) was considered to reflect statistical differences.
Deviations from mean values were expressed as the SEM.
Results
Renin stimulating properties of PTHrP and PTH in the
single-pass JFK
Flows and pressures. During the experimental period (110 to
200 mm) there were no significant differences between the six
groups with respect to kidney weights, mean perfusion pres-
sures or perfusate flow rates as well as the resulting renal
vascular resistances (Table 1). Since perfusate flow was ad-
justed during the first 30 minutes and kept constant throughout
the remainder of the experiment, the perfusion pressures were
continuously recorded during the experimental period. As
shown in Table I, the present methodology maintained the
overall variations of pressures within a narrow range during the
90 minute experimental period.
Comparison of renin release time courses from time-control
kidneys and kidneys exposed to graded concentrations of
hPTHrP-(1-34) and rPTH-(1-34) (groups 1 to 3). In time-control













Fig. 1. Renin release from single-pass IPK.
A. Comparison of renin release time courses
from time-control kidneys (group I; N = 5)
and kidneys exposed to graded concentrations
of hPTHrP-(l-34) (group 2; N = 5) or rPTH-
(1-34) (group 3; N 6). The increasing
concentrations of peptide were added for two
minutes every 18 minutes as indicated by the
striped and open areas of the top horizontal
bar. Data points represent the average of
renin release rate during consecutive six
minute periods of perfusate collection.
Statistical significance (P < 0.05) for a given
perfusion period was determined by
comparing time control IPK to either PTHrP-
or PTH-treated group (*) or by comparing
PTHrP-treated group to PTH-treated group
(#) as described in Methods. B. Comparison
of the net renin release responses to graded
concentrations of PTHrP (group 2) and PTH
(group 3). Data points represent the average
of net renin release rate over six minute
periods of perfusate collection, by subtracting
the basal renin release rate obtained from time
control IPK (group 1) during the
corresponding period. Statistical significance
(P < 0.05) for a given perfusion period was
determined by comparing PTHrP-treated
group to PTH-treated group (*) as described
in Methods. C. Comparison of the dose
response curves of PTHrP- and PTH-
stimulated renin release as calculated from A
and B. The data points represent the average
200 of net renin release rate calculated over the 18
minute period following peptide injections.
Asterisks indicate significant difference (P <
0.05) for a given peptide concentration.
from about 100 Ang I units to 40 Ang I units over the whole
experimental period (Fig. 1A). The fact that renin release
steady-state was not reached after 200 minutes of perfusion
prompted us to compare the time course of renin release rate
between control and peptide- or isoproterenol-treated IPK
groups over the 110 to 200 minute experimental period, during
which the perfusion pressure changes were limited.
PTHrP administration during two minutes every 18 minutes
(group 2) resulted in a concentration-dependent increase in the
mean renin release rate in these single-pass, stabilized pressure
perfused rat kidneys (Fig. 1A). A point-by-point comparison
(analysis of variance) with group I showed that the threshold
concentration of PTHrP that induced a significant increase of
the rate of renin release was 0.1 n, and maximal effect was
reached with 10 flM of PTHrP. Administration of PTH in the
same molar concentrations and under identical experimental
conditions also resulted in a concentration-related increase of
the mean renin release rate (group 3); however, the threshold
concentration of PTH was only 1 flM, while maximal effect was
reached with 100 nM of PTH (Fig. 1A).
—2 —1
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Perfusion time, minutes
For purposes of direct comparisons between PTHrP- and
PTH-induced responses, the renin release time courses plotted
in Figure lB have been presented as net increases by subtract-
ing the renin activity present in time control kidneys during the
same six minute perfusion period. A point-by-point comparison
(analysis of variance) showed that the extent of the responses to
0.1, 1 and 10 flM PTHrP was significantly higher than those
responses to PTH. In order to ensure that in these experiments
the renin secretory rates actually returned to baseline values,
renin activity released during the last 10 seconds before each
PTHrP or PTH addition was compared to that measured during
the corresponding six minute period in time-control IPK. As
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Table 2. Basal renin release checking points in groups 2 to 5 as
compared to time-control group 1 in single-pass IPK
Group I
(Time-control) Group 2 Group 3 Group 4 Group S
104 to 110 mm l09° to 110 mm
118±16 126± 21 110±11 84±18 ND
122 to 128 mm l27° to 128 mm
100±15 106± 14 96±10 104±26 85±14
140 to 146 Sn 145° to 146 mm
78±14 90± 15 80±10 78±22 77±6
158 to 164 mm l63° to 164 mm
67±9 69± 11 69±8 65±11 68±4
176 to 182 mm l81° to 182 mm
49±10 53± 8 66±9 60±13 ND
194 to 200 mm 199° to 200 mm
40±8 49± 10 58±8 60±12 59±4
In the analysis of variance for single factor experiments, the renin
release rates measured during the 10 second periods (called basal renin
release checking points) in groups 2 to 5, were not significantly different
(P > 0.1) from those measured during the corresponding 6 minute
periods in group 1 (time-control).
shown in Table 2, the renin release rates measured during these
so-called basal renin release checking points in group 2 and 3
were not significantly different from those measured over the
corresponding six minute periods in group 1. This observation
indicated that renin release returned to baseline level before
each peptide administration.
For purposes of direct comparison of PTHrP and PTH
concentration-related curves, the results of Figure lC have
been presented as the mean secretory rates over the 18 minute
periods which followed each peptide administration. In this
comparison, the concentration of rat PTH producing half-
maximal stimulation was 12 times higher (EC50 of 1.2 nM) than
that of human PTHrP (EC50 of 0.1 nM).
Effect of indomethacin on the PTHrP dose response (group
4). Group 4 was conducted to explore the role of cyclooxyge-
nase activity products in the responses to PTHrP observed in
group 2. As shown in Figure 2, during perfusion in the presence
of 0.1 [LM of indomethacin (group 4), renin release responses
were unchanged over an identical time sequence as in the
previous study (group 2). Again, the renin release rates mea-
sured during the basal renin release checking points in group 4
were not significantly different from those measured over the
corresponding six minute periods in group 1 (Table 2).
Comparative effects of maximal concentrations of rPTH-(1-
34), hPTHrP-(1-34) and isoproterenol (group 5). Group S was
conducted to compare the responses to the highest concentra-
tions of PTHrP and PTH to those induced by a known stimu-
lator of renin release. Isoproterenol at 0.1 jiM was used (Fig. 3).
The administration of 100 nM PTHrP for two minutes was
followed by 100 nrvi PTH 18 minutes later, and resulted in renin
release increases similar to those observed in groups 2 and 3
(Fig. 1B). However, if renin release rate returned to control
values within 18 minutes after PTHrP or PTH administration
(see group 5 in Table 2), the net renin released in response to
isoproterenol lasted at least 36 minutes. Thus, the mean secre-
tory rates in response to isoproterenol were 3.2 0.6 and 3.4
0.5 times higher than those to PTHrP and PTH, respectively.
Additivity of PTHrP- and PTH-induced renin release (group
6). The goal of the group 6 was to test the hypothesis that
PTHrP and PTH stimulate renin release via common action
sites. For that purpose, we determined whether maximal con-
centrations of PTHrP and PTH, administered together, resulted
in additive renin release responses or not, as compared to those
produced by each peptide alone. Expressed as mean secretory
rates over 18 minute periods, PTHrP and PTH (100 nM)
administered separately, increased renin release by 63 6 and
70 7 Ang I units, respectively, values similar to those shown
in Figure 1C (56 11 and 54 7 Ang I units, respectively). In
addition, the renin release responses to either PTHrP or PTH
were the same whether PTHrP was administered before PTH or
inversely, PTHrP and flH (100 nM) administered together
increased renin release by 64 6 Ang I units, a value very
similar to that obtained in response to each peptide alone.
Calcium dependency of renin stimulation by PTHrP in the
recirculating IPK
The second set of experiments was conducted to test the
hypothesis that the PTHrP-mediated renin release is dependent
on extracellular calcium. For that purpose we used a nonfilter-
ing rat IPK in order to minimize the interferences mediated by
macula densa mechanisms, with the responses of basal and
calcium-modulated renin release to PTHrP. It has previously
been shown that the use of low perfusion pressure together with
high perfusate oncotic pressure abolished the glomerular filtra-
tion [24J. Therefore, perfusate containing 10% BSA was used.
Because the single-pass IPK requires large volumes of perfu-
sate, and due to the cost of BSA, recirculating IPKs were
employed.
Flows and pressures. The experimental protocols used in this
series of experiments are summarized in Table 3, and the
perfusion flows are shown in Table 4. The mean perfusion flow
applied to reach 70 mm Hg in the four groups of IPK was 16.2
0.4 mI/mm x g, and it was not significantly different between
time-control and PTHrP-treated IPK. As perfusate flows were
adjusted during the first 10 to 15 minutes and kept constant
throughout the remainder of the experiment, the perfusion
pressures were recorded during the experimental period. As
shown in Figure 4, the perfusion pressures did not change
immediately after PTHrP injection. On the other hand, the
pressures slowly increased, especially in time-control IPK.
These increases were a little more obvious in time-control IPK
from the hypercalcic group (group B) where the perfusion
pressure reached 76.3 0.8 mm Hg at 90 minutes. PTHrP
seemed to protect the IPK from this small constriction in
hypercalcic (group B) and EGTA (group D) groups. Whatever,
the pressures of the IPK used for the present study may be
considered to have been maintained within a narrow range
between 35 and 90 minutes of perfusion, as the overall ampli-
tude in pressure variation did not exceed 6 mm Hg.
Calcium modulation of basal renin release. As a rule, the
renin activity in the recirculating perfusate rose spontaneously
with time in control preparations inside each group (Fig. 5). In
normocalcic medium (Fig. SA) renin activity reached a maximal
level at about 65 minutes and tended to stop thereafter. In
preliminary experiments these observations prompted us to
inject PTHrP after 70 minutes of equilibration; however, the
rise in perfusion pressure became too great in a number of IPK
after 90 to 100 minutes, especially those perfused with hyper-
calcic medium. Therefore, the time course of renin release













Fig. 2. Effect of indomethacin on PTHrP-
induced renin release in single-pass IPK.
Kidneys were perfused with increasing
concentrations of PTHrP for two minutes
every 18 minutes as indicated by the striped
and open areas of the top horizontal bar,
either in absence (0; group 2; N = 5) or
presence of 0.1 /LM indomethacin (•; group 4;
N = 4). Data points represent the average of
net renin release rate over six minute periods,
by subtracting the basal renin release rate
obtained from time control IPK shown in
Figure IA during the corresponding period of
perfusate collection.
Fig. 3. Comparison of net renin release
responses to maximal concentrations of
PTHrP, PTH and Isoproterenol (group 5; N
= 4) in single-pass JPK. Peptides and
isoproterenol were added for two minutes
every 18 minutes, as indicated by the striped
and open areas of the top horizontal bar. Data
points represent the average of net renin
release rate over a six minute period, by
subtracting the basal renin release rate200 obtained from time control IPK shown in
Figure 1A during the corresponding period of
perfusate collection.
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Perfusion time, minutes
between time control and PTHrP-treated preparations was
compared over a 35 to 90 minute period, during which the
perfusion pressure variations were limited. The comparison
between the time course of spontaneous basal renin release
(time control) indicated that the extent of renin activity which
accumulated over the 35 to 90 minute time interval (Fig. 5) or
the renin secretory rates over the 35 to 50, 50 to 65, 65 to 80 and
80 to 90 minute periods (Fig. 6) varied significantly with
perfusate ionized calcium concentration or calcium effector
addition. Increasing ionized calcium to 2 m (panel B) or
adding BAY-K8644 (panel C) decreased the amount of basal
renin released or the mean secretory rates as compared to
normocalcic time-control IPK (panel A). On the other hand, the
use of calcium-free perfusate (panel D), though not obvious,
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"normocalcic," CTL 6 1 mt.i none none
"normocalcic," PTHrP 6 1 mM none 125 nM
Group B
"hypercalcic," CTL 6 2 m none none
"hypercalcic," PTHrP 6 2 mri none 125 nM
Group C
"BAY-K8644," CTL 4 1 mrs 20 nM
BAYK8644b
none




"EGTA," CTL 6 <0.01 mat 2 mat EGTAC none
"EGTA," PTHrP 6 <0.01 mat 2 mat EGTA 125 nM
N is the number of independent IPK preparations. Note that in each
experimental group, the N time-control (CTL) IPK and the N PTHrP-
treated IPK are separate kidney preparations.
a hPTHrP-(1-34) was administered at 38 minutes.b BAY-K8644 was administered between 10 and 15 minutes.
EGTA was included during perfusate preparation.
tended to increase the spontaneous basal renin release espe-
cially during the 50 to 90 minute period as compared to
normocalcic time-control IPK (panel A).
Calcium modulation of PTHrP-stimulated renin release.
With normocalcic medium, renin release in the presence of
PTHrP rose for up to 80 minutes, reaching a maximal value of
935 106 Ang I units, which was 1.6 times higher than in the
control where a near maximal value was reached at 65 minutes.
PTHrP increased the secretory rate (Fig. 6A) after the first 15
minutes following PTHrP injection and over the subsequent 50
to 65 and 65 to 80 minute periods. In both the initial (0 to 35
minutes, before PTHrP injection) and the final (80 to 90 min-
utes) periods, the mean secretory rates were similar. With
hypercalcic medium (Fig. SB) renin activity rose up to 80
minutes and reached 657 76 Ang I units, which was 1.7-fold
higher than in the corresponding time-control IPK. The PTHrP
induced increase of the mean secretory rate was significant only
during the 35 to 50 minute interval of time, reaching a value of
22.1 1.9 Ang I units/mm versus 10.1 1.6 Ang I units/mm in
the corresponding time-control IPK (Fig. 6B). With perfusate
containing 20 nat BAY-K8644, the stimulating action of PTHrP
on renin release was even more obvious (Fig. SC). Renin
activity rose up to 80 minutes and reached 489 128 Ang I
units, which was about three times higher than in the corre-
sponding time-control IPK. In the same way, PTHrP markedly
increased the mean secretory rates after peptide injection up to
80 minutes, whereas no difference was seen during the 0 to 35
minute period and the 80 to 90 minute period (Fig. 6C).
Conversely, PTHrP had no effect on the basal renin release
enhanced by calcium-free EGTA medium (Figs. SD and 6D).
Discussion
Evidence for direct renin stimulatory properties of PTHrP
In both single-pass and recirculating constant-flow perfused
isolated rat kidneys, the low perfusion pressure and the absence
of preexisting vascular tone suppressed the renal vasodilating
Table 4. Perfusion flows in the four groups of recirculating IPK
IPK Groups Time-control PTHrP-treated
Group A 19.0 1.9 16.8 1.5
Group B 15.7 1.1 16.3 1.1
Group C 16.3 1.8 15.2 1.8
Group D 15.5 1.1 14.8 0.4
Flows applied to reach about 70 mm Hg are expressed as ml/min/g
kidney weight. A, B, C and D refer to the experimental conditions
described in Table 3.
effect of PTHrP and PTH, as previously described by this
laboratory [17, 201 using isolated preconstricted rat kidneys.
The perfusion pressures were maintained within a narrow range
during the experimental periods to avoid or minimize the effects
of hemodynamic changes on renin release. These findings
indicate that the baroreceptors would not be responsible for the
renin release responses. Under these conditions, the present
results are clear evidence that hPTHrP-(l-34) is able to stimu-
late renin secretion from rat kidney. In addition, the fact that
this effect is also displayed by nonfiltering IPK, suggests that
the variations in renin release were independent from tubular
and macula densa-mediated mechanisms. Taken together, these
findings indicate that the variations of renin release to both
PTHrP and PTH originated mainly from juxtaglomerular renin-
secreting cells.
In the single-pass IPK, PTHrP stimulates renin release with a
potency twelve times higher than PTH (EC5Ø = 0.1 nM) and a
threshold concentration inducing a significant increase of renin
release of 0.01 nM. PTHrP differs from known local renin
release promoters, such as isoproterenol, by its short-lasting
action (Fig. 3). PTHrP exhibits a number of properties on the
renal vasculature: it binds to specific renal arteriolar receptors
[161 and stimulates adenylyl cyclase in these vessels [17]; it also
vasodilates the renal artery [7] and the isolated rat kidney [17].
Rocacusachs, Dipette and Nickols [61 showed in vivo that
PTFIrP decreases renal vascular resistance without affecting
renal blood flow. We now report that PTHrP is, like many renal
vasodilators, an effective renin secretion promoter.
This combination of properties is highly suitable for signifi-
cant modulatory activities of PTHrP on normal renal hemody-
namics. Also, a large number of normal human and animal
tissues contain immunoreactive PTHrP or express mRNA for
PTHrP, suggesting paracrine or autocrine functions for this
peptide [8—151. However, it is still undetermined whether
mRNA for PTHrP or PTHrP itself is present or not in the renal
vascular smooth muscle cells, but they have been found in a
large number of extra-renal vascular tissues. Therefore, a role
for PTHrP in the regulation of renal microcirculation is sug-
gested by these findings, but clearly remains unproven. In this
respect, the recent findings of Rocacusachs, Dipette and Nick-
ols [6] are of particular interest. In their in vivo studies, PTHrP
decreased renal vascular resistance without affecting blood
flow, while inducing a marked systemic vasodilation and a
reduction in mean arterial pressure. In parallel, PTHrP de-
creased blood flow to the brain and the splanchnic organs, but
did not change vascular resistance in these organs. In the light
of these results the authors proposed that the reduction in blood
pressure most likely resulted in the reflex activation of compen-
satory pressor systems such as the renin-angiotensin system,
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Fig. 4. Time course of perfusion pressure in
the four groups of recirculating IPK. (A)
"normocalcic," B "hypercalcic," C "BAY-
K8644 and D "EGTA" refer to the
experimental conditions described in Table 3.
The mean SEM are shown. Asterisks
indicate significant differences between time-
control (0) and PTHrP-treated (•) kidney
preparations for a given perfusion time (P <
0.05).
Fig. 5. Comparison of the time course of the
perfusate renin activity concentration between
time-control and PTHrP-treated recirculating
IPK under various calcium conditions. IPK
were perfused with "normocalcic" A,
"hypercalcic" B, "BAY-K8644" C and
"EGTA" D media as described in Table 3.
Results are presented as the net renin activity
increase from the end of the initial 35 minute
period. The mean levels (± SEM) of perfusate
renin activities reached at 35 minutes were
561 70 (A), 414 98 (B), 378 53 (C) and
484 62 Ang I units (D) in time control IPK
(0). In PTHrP-treated IPK (•), the 35 minute
renin activities were 503 89 (A), 374 89
(B), 378 42 (C) and 482 71 Ang I units
(D). Asterisks indicate significant differences
between time control and PTHrP-treated IPK
for a given perfusion time.
Fig. 6. Comparison of the time course of the
augmentation rate of the perfusate renin
activity concentration between time control
and PTHrP-ireated recirculating IPK perfused
under various calcium conditions. IPK were
perfused with "normocalcic" A,
"hypercalcic" B, "BAY-K8644" C, and
"EGTA" D media as described in Table 3.
These renin release rates were calculated from
the data presented in Figure 5 as described in
Methods. Asterisks indicate significant
differences between time control (0) and
PTHrP-treated () IPK for a given perfusion
period.
which in turn, might offset the vasodilatory properties of PTHrP
in the splanchnic bed. The findings of the present report
strongly support such a hypothesis. Thus, it may be of some
interest to postulate that, by its action on renin release, PTHrP
could contribute to the maintenance of renal blood flow in the
face of a reduced systemic pressure. But this assumption
clearly needs further investigations.
Insight into the mechanism of the renin stimulating properties
of PTHrP
In the time-control recirculating IPK, we observed that renin
release increased spontaneously and then reached a maximal
level between 50 and 65 minutes and tended to stop thereafter.
A similar pattern of renin release accumulation with time was
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observed by Cohen et a! [29], who showed that hyperoncotic
perfusate increased basal renin release from isolated nonfilter-
ing rat kidneys over a period of 70 minutes. In addition,
infraphysiologic perfusion pressure used to abolish glomerular
filtration may also be involved in the spontaneous increase of
renin release during the first 50 to 65 minutes.
The concept that renin secretion is inversely related to
extracellular ionized calcium concentration [18, 19, 30, 31] is
further documented by the present study. Indeed, increasing
the extracellular calcium inhibited renin release, whereas re-
moving extracellular calcium enhanced renin release, Accord-
ingly, BAY-K8644, an analog of the dihydropyridine calcium
antagonist nifedipine, which enhances calcium influx through
the voltage-dependent channels [32], depressed renin release.
PTHrP was unable to further increase basal renin release in
absence of extracellular calcium. Conversely, PTHrP strongly
reversed the basal renin release depressed by the increase of
extracellular calcium or in response to BAY-K8644. These
findings suggest that PTHrP stimulates renin release from IPK
through a calcium-dependent process. At this point, the ques-
tion of whether PTHrP inhibits calcium entry in renin secreting
cells as it has been suggested previously for PTH in vascular
smooth muscle cells [33—35], requires direct measurements of
cytosolic calcium. However, another possibility is that basal
and stimulated renin releases are derived from different intra-
cellular pools controlled by different mechanisms. Thus, it is
possible that basal renin release is derived from one pool which
is inhibited by rises in intracellular calcium. A second pool may
be coupled to local rises in intracellular calcium and be depen-
dent on extracellular calcium. As PTHrP stimulates adenylyl
cyclase activity in renal renin containing arterioles [171, the
possibility exists that PTHrP promotes renin release by a
process depending on both cAMP generation and extracellular
calcium. In the present work, we also demonstrate that the
products of cyclooxygenase activity do not account for the
stimulatory properties of PTHrP on renin release. In other
respects, the lack of additivity of the renin release responses to
PTHrP and PTH suggests that these peptides stimulate renin
release by interaction with common action sites. Further inves-
tigations such as binding studies are needed to assess this
conclusion.
In summary, the data presented here support a stimulatory
role for PTHrP on renin release. This effect is dependent on
extracellular calcium and independent on baroreceptors, mac-
ula densa and prostaglandin synthesis. Finally, PTHrP action
on renin release most likely results from activation of renal
vascular PTH action sites.
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